Sanofi - Asset Resilience Ratio
Sanofi (SNYN) has an Asset Resilience Ratio of 0.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Sanofi PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Sanofi's Asset Resilience Ratio has changed over time. See Sanofi balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Sanofi's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SNYN company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | MX$0.00 | 0% |
| Short-term Investments | MX$810.00 Million | 0.64% |
| Total Liquid Assets | MX$810.00 Million | 0.64% |
Asset Resilience Insights
- Limited Liquidity: Sanofi maintains only 0.64% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sanofi Industry Peers by Asset Resilience Ratio
Compare Sanofi's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
Organon & Co
NYSE:OGN |
Drug Manufacturers - General | 4.46% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.10% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198 |
Drug Manufacturers - General | 0.46% |
Annual Asset Resilience Ratio for Sanofi (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Sanofi.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.64% | MX$810.00 Million ≈ $46.62 Million |
MX$126.81 Billion ≈ $7.30 Billion |
+0.27pp |
| 2024-12-31 | 0.37% | MX$486.00 Million ≈ $27.97 Million |
MX$132.80 Billion ≈ $7.64 Billion |
+0.15pp |
| 2023-12-31 | 0.21% | MX$270.00 Million ≈ $15.54 Million |
MX$126.46 Billion ≈ $7.28 Billion |
-0.32pp |
| 2022-12-31 | 0.53% | MX$664.00 Million ≈ $38.21 Million |
MX$124.58 Billion ≈ $7.17 Billion |
-0.34pp |
| 2021-12-31 | 0.88% | MX$1.05 Billion ≈ $60.66 Million |
MX$120.24 Billion ≈ $6.92 Billion |
+0.09pp |
| 2020-12-31 | 0.79% | MX$900.00 Million ≈ $51.80 Million |
MX$114.53 Billion ≈ $6.59 Billion |
+0.41pp |
| 2019-12-31 | 0.38% | MX$426.00 Million ≈ $24.52 Million |
MX$112.74 Billion ≈ $6.49 Billion |
+0.20pp |
| 2018-12-31 | 0.18% | MX$199.00 Million ≈ $11.45 Million |
MX$111.41 Billion ≈ $6.41 Billion |
+0.10pp |
| 2017-12-31 | 0.08% | MX$77.00 Million ≈ $4.43 Million |
MX$99.83 Billion ≈ $5.75 Billion |
+0.05pp |
| 2016-12-31 | 0.03% | MX$31.00 Million ≈ $1.78 Million |
MX$104.67 Billion ≈ $6.02 Billion |
+0.02pp |
| 2015-12-31 | 0.01% | MX$13.00 Million ≈ $748.15K |
MX$102.32 Billion ≈ $5.89 Billion |
+0.00pp |
| 2014-12-31 | 0.01% | MX$9.00 Million ≈ $517.95K |
MX$97.39 Billion ≈ $5.60 Billion |
-0.05pp |
| 2013-12-31 | 0.06% | MX$59.00 Million ≈ $3.40 Million |
MX$96.06 Billion ≈ $5.53 Billion |
-- |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, ty… Read more